Annexon Expands Board of Directors with Appointment of William “BJ” Jones
Annexon, Inc., a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has appointed William “BJ” Jones to its board of directors. Jones brings over three decades of experience in the biotechnology industry, enhancing the company's leadership in commercial operations.
Annexon to Present at Major Healthcare Conferences
Annexon announced that its president and CEO, Douglas Love, will present at the 43rd Annual J.P. Morgan Healthcare Conference and the Jefferies London Healthcare Conference. These presentations will cover the company's advancements in treating neuroinflammatory diseases and its late-stage clinical platform.
Positive Results from Clinical Trials
Annexon reported positive topline results from a real-world evidence study comparing its ANX005 treatment to standard treatments for Guillain-Barré Syndrome (GBS). The study showed early and greater benefits of ANX005 in muscle strength and functional outcomes. Additionally, Annexon is actively enrolling participants for its Phase 3 ARCHER II trial for ANX007 in Geographic Atrophy (GA), with data expected in the second half of 2026.
Annexon's Financial and Portfolio Updates
The company also provided updates on its financial status and portfolio, including the initiation of dosing in the ARCHER II registrational trial for ANX007 and the transition of its first-in-kind oral C1s inhibitor, ANX1502, to an enhanced tablet formulation. Annexon anticipates submitting a Biologics License Application (BLA) for ANX005 in the first half of 2025.
Annexon's Commitment to Advancing Neuroinflammatory Disease Treatments
Through strategic leadership appointments, participation in key healthcare conferences, and positive clinical trial results, Annexon, Inc. continues to demonstrate its commitment to advancing treatments for neuroinflammatory diseases affecting the body, brain, and eye.
